Cannabigerol in supplements: Lygos partners with OBX to develop nutraceuticals
07 Oct 2020 --- Sustainable specialty ingredient provider Lygos has partnered with Open Book Extracts (OBX), a cannabinoid health and wellness company, to develop nutraceutical supplement products featuring Lygos’ cannabigerol (CBG).
OBX and Lygos will incorporate CBG and its anti-inflammatory properties into a new line of nutraceutical supplement products to better serve the growing global demand for cannabinoid-enabled benefits.
“Together with OBX, we are poised to transform the traditional nutraceutical market with these next-generation CBG-based supplements,” supports Eric Steen, CEO of Lygos.
“Our modular production platform enables us to produce a wide range of cannabinoids for different applications. We will continue to join forces with industry leaders, such as OBX, which are known for delivering high-quality consumer products,” he says.
The companies peg Lygos’ CBG as the “first cannabinoid” and highlight it as pure, tetrahydrocannabinol (THC)-free and environmentally sustainable.
“We are working with Lygos to leverage its proprietary cannabinoid production platform to make a line of innovative consumer products,” comments Dave Neundorfer, CEO of Open Book Extracts.
“OBX and Lygos share a vision of creating the most consistent, pure and safe cannabinoid products on the market. Lygos’ production technology now gives us access to any cannabinoid, even rare cannabinoids, which will enable us to enter new markets with high-quality products in the future,” Neundorfer adds.
The proprietary cannabinoid production platform is a direct result of the recent acquisition of Librede – a multi-interdisciplinary natural product company that utilizes the tools of synthetic biology and chemistry to produce high-value natural products.
In addition, CBG also derived from the integration and validation of additional Lygos technology advances, the company says. The combined Librede and Lygos technologies enable the production of any cannabinoid and cannabinoid-based product of interest in an environmentally safe, sustainable and cost-effective manner at industrial scale for numerous consumer markets.
Cannabinoids star in NPD
In the same space, CannaCraft has relaunched its popular wellness brand, Care By Design, with more cannabinoids, terpenes and flavonoids.
Available in tinctures, soft gels, gummy bites, vape cartridges and pain cream, the enhanced formulations offer a wide array of ratios and high cannabinoid content. Offerings include a new 40:1 ratio of CBD to THC for consumers seeking strong CBD relief and the benefits of full-spectrum cannabis without the intoxicating effects.
“We reformulated Care By Design to offer a more robust product at the same price to provide customers extra relief during these stressful times,” notes Jim Hourigan, CannaCraft’s chief executive.
“The additional ingredients harness the full power of the plant and aid cannabis’ entourage effect at no additional cost to our customers,” he adds.
The refreshed Care By Design line starts with full-spectrum winterized cannabis oil as the base and is enhanced with minor cannabinoids, cannabis terpenes, and flavonoids. The company recently introduced a dual-processing method to capture more components, most notably CBDA and THCA, two non-intoxicating minor cannabinoids with promising potential.
Furthermore, Criticality, a North Carolina-based industrial hemp company, introduced its latest CBD product innovation to the market: CBD Body Lotion. The product is designed to help address dry and sensitive skin.
“We created our new CBD Body Lotion to help our consumers combat dry skin. It’s ideal for daily use, helping to soothe the skin, and contains natural oils, including hemp oil, which helps instill moisture,” says Brian Moyer, Criticality’s CEO.
All hemp-derived products produced by Criticality, including its Korent and Korent Select CBD body lotions, are made from hemp grown in US-based family farms. Prior to processing, the hemp is tested and analyzed to help ensure safety, quality, and compliance with applicable laws and regulations.
Cellibre Inc. recently closed an “oversubscribed” round of bridge financing to bring its fermented cannabinoids closer to commercialization. Meanwhile, Amyris successfully scaled up the commercial production of CBG, which is produced via industrial fermentation.
By Kristiana Lalou
To contact our editorial team please email us at editorial@cnsmedia.com
Subscribe now to receive the latest news directly into your inbox.